SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 /PRNewswire/ --  VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system ( CNS ) disorders, today reported financial results for

- McPartland brings over 20 years of experience in business and corporate development, capital markets, corporate communications and executive management consulting - SOUTH SAN FRANCISCO, Calif., Oct. 4, 2016 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN) ( VistaGen  or the  Company

- Company poised to achieve multiple key corporate, business, clinical and regulatory milestones in the near-term - SOUTH SAN FRANCISCO, Calif., Sept. 22, 2016 /PRNewswire/ --  VistaGen Therapeutics Inc.  (NASDAQ: VTGN) ( VistaGen  or the  Company ), a clinical-stage biopharmaceutical company

- Former Clinical Lead for Neuropsychiatry at Teva Pharmaceuticals to lead clinical development of AV-101 in major depressive disorder (MDD) and additional CNS pipeline programs SOUTH SAN FRANCISCO, Calif., June 20, 2016 /PRNewswire/ --  VistaGen Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., May 16, 2016 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (NASDAQ: VTGN) (VistaGen), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central

- Company Uplisting to NASDAQ Capital Market Under New Ticker "VTGN" Effective May 11, 2016 - SOUTH SAN FRANCISCO, Calif., May 10, 2016 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and

SOUTH SAN FRANCISCO, Calif., March 30, 2016 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving

- Sanjay Mathew, M.D., expert in the psychopharmacological management of depressive and anxiety disorders, appointed as Board member - - Thomas Laughren, M.D., expert in the safety and efficacy of psychiatric drugs with nearly 30 years of experience at the FDA, appointed as Board member - -

New Licenses Expand Core Drug Rescue Programs and Collaborative Regenerative Medicine Opportunities Related to Heart Disease, Liver Disease and Osteoarthritis SOUTH SAN FRANCISCO, Calif., Dec. 23, 2015 /PRNewswire/ -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical

SAN FRANCISCO, Nov. 3, 2015 /PRNewswire/ -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today